Kailera Therapeutics (NASDAQ: KLRA) Received Sweeping Positive Analyst Coverage Following Its August 12 Q2 2026 Earnings Report Confirming an Active Investigational New Drug (IND) Application With the FDA for Ribupatide Oral (KAI-9531-T) and Global Phase 3 Obesity Trials Planned for H1 2027, With 6 Analysts Averaging a Strong Buy Rating and a $42.60 12-Month Price Target (Representing 82.83% Upside From the $17.95-$19.50 Trading Range on August 13-14), Including TD Cowen at Buy With a $57 Price Target, Evercore ISI at Outperform, and William Blair at Outperform; The Company Holds Cash, Cash Equivalents, and Marketable Securities Expected to Support Execution of Multiple Clinical Milestones With Runway Into Mid-2028; Ribupatide Is a Once-Weekly GLP-1/GIP Dual Agonist Peptide That Reached 23.6% Mean Weight Loss at 8 mg Over 36 Weeks in Phase 2 Injection Trial, With the Oral Formulation Reaching Up to 12.1% Weight Loss and 38.6% of Participants Achieving ≥15% Loss in Hengrui's Phase 2 Trial
Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.